Palatin Technologies (NYSE American: PTN), a pioneering biopharmaceutical company renowned for developing first-in-class medicines that modulate the melanocortin peptide receptor system, is excited to announce that it has raised $4,700,000 in new funding. This significant capital infusion will accelerate the company’s mission of addressing unmet medical needs by advancing innovative therapeutics for conditions beyond its groundbreaking Vyleesi®, the only on-demand, FDA-approved treatment for premenopausal women suffering from hypoactive sexual desire disorder (HSDD). With Vyleesi® already transforming lives by offering much-needed treatment where few alternatives exist, this new funding will bolster Palatin’s expanding pipeline, particularly in areas where the melanocortin system plays a critical role in resolving harmful inflammation.
The investment will primarily support the development of PL9643, Palatin’s most advanced ocular candidate aimed at treating dry eye disease, which is scheduled to enter Phase 3 clinical trials in the second half of 2021. Additionally, the funds will help propel early-stage studies targeting other ophthalmic indications such as non-infectious uveitis, retinopathies, and corneal diseases, as well as new proof-of-concept clinical studies in ulcerative colitis and kidney disease. These initiatives underscore Palatin’s commitment to leveraging its deep expertise in melanocortin biology to create broad utility therapeutics that can transform the treatment landscape for inflammatory and degenerative conditions. The company is enthusiastic about the potential of these therapies not only to improve patient outcomes across multiple disease areas but also to deliver significant value to its shareholders. This funding marks an important milestone and reinforces Palatin Technologies’ vision for a healthier future through innovative drug development.
